AGN - Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases
Market Assessment
Enanta (ENTA) is a small cap ($1.63B) biopharma with a focus on developing innovative therapeutics for viral infections and liver diseases. Enanta gained clinical and investor prominence with the approval of the HCV therapeutics, glecaprevir and paritaprevir, commercialized with AbbVie (ABBV). Some may wonder what happens to Enanta’s license agreement with AbbVie given its recently planned acquisition of Allergan (AGN). I don’t foresee any change(s) to the agreement. But the question to be asked is if AbbVie would have any future clinical interest in EDP-305, an FXR